All PlansCoverageHigh impact
Recall: Insulin Glargine
UPMC Health Plan·Endocrinology, Pharmacy, Internal Medicine +1 more·Pharmacy
Effective date
Jul 1, 2022
We identified it
Aug 7, 2026
Summary
Mylan Pharmaceuticals has issued a recall of one batch of Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL, 3 mL prefilled pens. The billing team must identify patients who received this recalled batch and coordinate with providers to ensure affected patients are notified and transitioned to alternative insulin products.
Action Required
Immediately: Billing and clinical teams must identify all claims processed for Insulin Glargine (HCPCS J7364) from the recalled batch. Coordinate with providers to: (1) review patient records for the specific recalled batch, (2) notify affected patients of the recall, (3) arrange alternative insulin therapy, and (4) reprocess claims with replacement insulin product codes as appropriate. Update your pharmacy benefit system to flag any remaining prescriptions from this batch. Failure to identify and manage affected patients may result in clinical harm and potential liability.